Walgreens beats third quarter earnings estimates on pharmacy sales growth

Walgreens Boots Alliance (WBA) reported better-than-expected fiscal third-quarter earnings, with adjusted EPS of $0.38 surpassing consensus estimates of $0.34, on sales that grew 7.2% year-over-year to $38.99 billion. This performance was primarily driven by robust pharmacy sales and international segment growth, despite ongoing weakness in its U.S. front-end retail. Amidst its ongoing privatization process by Sycamore Partners, Walgreens has withdrawn its financial guidance for fiscal 2025 as it focuses on its turnaround strategy.

Analysis

Walgreens Boots Alliance (WBA) reported a solid fiscal third quarter, exceeding analyst expectations on both revenue and earnings. Sales grew 7.2% year-over-year to $38.99 billion, significantly ahead of the $36.59 billion consensus, propelled by identical 7.8% growth in both its US Retail Pharmacy and International segments. Adjusted earnings per share came in at $0.38, surpassing the Wall Street estimate of $0.34. According to CEO Tim Wentworth, this performance reflects progress in the US Healthcare segment and the success of cost-saving initiatives. However, this strength is partially offset by admitted persistent weakness in US front-end retail sales, indicating an ongoing operational challenge. The most significant factor influencing the company's trajectory is the pending privatization led by Sycamore Partners, which has led WBA to withdraw its fiscal 2025 financial guidance. This removal of forward-looking visibility, combined with the complexities of the buyout, likely explains the stock's muted 0.8% rise, as market participants weigh the positive current results against future uncertainty.

Key Decisions for Investors

• The primary driver for WBA's equity value is now the pending privatization by Sycamore Partners, making the stock's performance highly dependent on deal-related news and arbitrage rather than standalone operational results.
• Given the withdrawal of fiscal 2025 guidance, investors lack official benchmarks for future performance, increasing uncertainty and making fundamental valuation models less reliable until the privatization process concludes.
• Investors should monitor for any recovery in the challenged US front-end retail sales, as this remains a critical weak point mentioned by management and a key aspect of the long-term turnaround strategy.